(12) United States Patent (10) Patent No.: US 7,585,859 B2 Ibrahim Et Al
Total Page:16
File Type:pdf, Size:1020Kb
US007585859B2 (12) United States Patent (10) Patent No.: US 7,585,859 B2 Ibrahim et al. (45) Date of Patent: Sep. 8, 2009 (54) PDE4B INHIBITORS AND USES THEREFOR 5,800,992 A 9, 1998 Fodor et al. 5,807,522 A 9, 1998 Brown et al. (75) Inventors: Prabha N. Ibrahim, Mountain View, CA (US); Hanna Cho, Oakland, CA 5,830,645 A 11/1998 Pinkel et al. (US); Bruce England, Hayward, CA 5,840,485 A 11/1998 Leblet al. (US); Sam Gillette, Oakland, CA (US); 5,856,174 A 1/1999 Lipshutz et al. Dean R. Artis, Kensington, CA (US); 5,877,007 A 3/1999 Housey Rebecca Zuckerman, Alameda, CA 5,922,557 A T/1999 Pon (US); Chao Zhang, Moraga, CA (US) 5,959,098 A 9/1999 Goldberg et al. (73) Assignee: Plexxikon, Inc., Berkeley, CA (US) 5,965,452 A 10, 1999 Kovacs 6,013,440 A 1/2000 Lipshutz et al. (*) Notice: Subject to any disclaimer, the term of this 6,022,963 A 2/2000 McGallet al. patent is extended or adjusted under 35 6,025,155 A 2/2000 Hadlacsky et al. U.S.C. 154(b) by 592 days. 6,045,996 A 4/2000 Croninet al. (21) Appl. No.: 11/123,893 6,048,695 A 4/2000 Bradley et al. 6,054,270 A 4/2000 Southern (22) Filed: May 6, 2005 6,090,912 A 7/2000 Leblet al. 6,096,718 A 8, 2000 Weitzman et al. (65) Prior Publication Data 6,107.478 A 8, 2000 Pederson et al. US 2006/OO41 OO6A1 Feb. 23, 2006 6,110,456 A 8/2000 During Related U.S. Application Data 6,110,458 A 8, 2000 Freeman et al. 6,113,913 A 9/2000 Brough et al. (60) Provisional application No. 60/569,435, filed on May 6,117,681 A 9, 2000 SalmonSet al. 6, 2004. 6,178,384 B1 1/2001 Kolossváry (51) Int. Cl. 6,243,980 B1 6/2001 Bronstein et al. A 6LX 3/5.377 (2006.01) 6,258,606 B1 7/2001 Kovacs A6 IK 3L/4525 (2006.01) 6,261,776 B1 7/2001 Pirrung et al. A6 IK 3/422 (2006.01) CO7D 413/14 (2006.01) CO7D 409/4 (2006.01) CO7D 26L/06 (2006.01) (Continued) (52) U.S. Cl. .................... 514/236.8; 514/326; 514/378: 544/137:546/209: 548/248 FOREIGN PATENT DOCUMENTS (58) Field of Classification Search ................. 514/444, EP O154734 9, 1985 514/445, 447, 448, 473, 471, 422, 423, 236.8, 514/326, 378; 549/59, 60, 63, 64, 473, 480; 548/530,517, 248; 54.4/137; 546/209 See application file for complete search history. (Continued) (56) References Cited OTHER PUBLICATIONS U.S. PATENT DOCUMENTS Wolff et al., Burger's Medicinal Chemistry and Drug Discovery, 4,150,949 A 4, 1979 Smith 1994, Wiley-Interscience, Fifth Edition, vol. I: Principles and Prac 4,568,649 A 2/1986 Bertoglio-Matte tice, pp.975-977.* 4,626,513 A 12/1986 Burton et al. 4,861,891 A 8, 1989 Saccomano et al. (Continued) 5,143,854 A 9/1992 Pirrung et al. 5.426,039 A 6, 1995 Wallace et al. Primary Examiner Kamal A Saeed 5.434,049 A 7, 1995 Okano et al. Assistant Examiner—Kristin Bianchi 5.449,614 A 9, 1995 Danos et al. (74) Attorney, Agent, or Firm Foley & Lardner LLP 5,474,935 A 12/1995 Chatterjee et al. 5,556,752 A 9, 1996 Lockhart et al. (57) ABSTRACT 5,580,859 A 12/1996 Felgner et al. 5,631,236 A 5, 1997 Woo et al. 5,632,957 A 5, 1997 Heller et al. 5,658,775 A 8, 1997 Gilboa Compounds active on phosphodiesterase PDE4B are pro 5,700,637 A 12/1997 Southern vided. Also provided herewith are compositions useful for 5,721,118 A 2, 1998 Scheffler treatment of PDE4B-mediated diseases or conditions, and 5,744,305 A 4, 1998 Fodor et al. methods for the use thereof. 5,747,276 A 5, 1998 Hochet al. 5,763,198 A 6, 1998 Hirth et al. 5,770.456 A 6, 1998 Holmes 9 Claims, 5 Drawing Sheets US 7,585,859 B2 Page 2 U.S. PATENT DOCUMENTS Alfthan, "Surface plasmon resonance biosensors as a tool in antibody engineering.” Biosensors & Bioelectronics. 13:653-63 (1998). 6,277,489 B1 8, 2001 Abbott et al. al-Obeidi. “Peptide and Petidomimetic Libraries' Mol Biotechnol 6,277,628 B1 8/2001 Johann et al. 9(3): 205-23 (1998). 6,288,234 B1 9, 2001 Griffin Amersdorfer P. Marks JD., “Phage Libraries for Generation of Anti 6,294,330 B1 9, 2001 Michnicket al. botulinum scFv Antibodies.” Methods in Molecular Biology, 6,500,610 B1 12/2002 Pamukcu et al. 145:219-40 (2001). 6,559,168 B2 5, 2003 Marfat et al. Bartlett et al., "Caveat: A Program to Facilitate the Structure-derived 2001/OOO8765 A1 7/2001 Shinoki et al. Design of Biologically Active Molecules,” in Chemical and Biologi 2001/OO.12537 A1 8/2001 Anderson et al. cal Problems in Molecular Recognition, Roberts, S.M.; Ley, S.V.; 2001 OO14448 A1 8/2001 Chappa et al. Campbell, M.M. eds.; Royal Society of Chemistry: Cambridge, pp. 2001 OO14449 A1 8/2001 Nerenberg et al. 182-196 (1989). 2001 OO16322 A1 8, 2001 Caren et al. Bagshaw, C.R. and Harris, D.A., “Measurement of Ligand Binding to 2001 OO18642 A1 8, 2001 Balaban et al. Proteins.” Spectrophotometry and Spectrofluorometry. A Practical 2001 OO19827 A1 9, 2001 Dawson et al. Approach, Bashford, C.L. and Harris, D.A., eds.; pp. 91-114, IRL 2002fOOO9764 A1 1/2002 Thompson et al. Press Ltd., Oxford, U.K., (1987). 2002fO165237 A1 11/2002 Fryburg et al. Beavo, et al., “Multiple Cyclic Nucleotide Phosphodiesterases.” Mol. 2003, OO643.74 A1 4/2003 Ait Ikhlefet al. Pharmacol., 46:399-405 (1994). 2004/0106641 A1 6/2004 Hofgen et al. Bell, J.E., Spectroscopy. In Biochemistry, vol. I, pp. 155-194, CRC Press, (1981). FOREIGN PATENT DOCUMENTS Berthet, et al., “The Assay of Glucagon and Epinephrine with Use of EP O 667 345 8, 1995 Liver Homogenates.” J. Biol. Chem., 229:351-361 (1957). EP 1 166785 1, 2002 Blundell et al., “Knowledge-based protein modeling and design.” WO WO96, 17958 6, 1996 Eur: J. Biochem., 172:513-520 (1988). WO WO96, 18738 6, 1996 Böhm, H., “On the use of LUDI to search the Fine Chemicals Direc WO WO 97/46313 12/1997 tor for ligands of proteins of known three-dimensional structure. J. WO WO 98/37078 A1 * 8, 1998 Comp. Aided Molec. Design 8: 623-632 (1994). WO WO98,45268 10, 1998 Bolger et al., “A Family of Human Phosphodiesterases Homologous WO WO99/O9217 4f1999 to the dunce Learning and Memory Gene Product of Drosophila WO WO99f2O625 4f1999 melanogaster Are Potential Targets for Antidepressant Drugs.” Mol. WO WO99,21845 5, 1999 Cell. Biol. 13 (10), 6558-6571 (1993). WO WO 99.51773 10, 1999 Bolger, G.B., “Molecular Biology of the Cyclic AMP-Specific Cyclic WO WOO1/02369 1, 2001 Nucleotide Phosphodiesterases: A Diverse Family of Regulatory WO WO 2005, 016924 2/2005 Enzymes.” Cell Signal, 6:851-859 (1994). WO WO O2/O62290 8, 2006 Borch, et al., “Lithium Cyanohydridoborate, a Versatile New Reagent.” J. Am. Chem. Soc., 91,3996-3997 (1969). OTHER PUBLICATIONS Bowtell, D. "Options available—from start to finish—for obtaining expression data by microarray.” Nature Genetics Supp. 21:25-32 Card et al., Structural basis for the activity of drugs that inhibit phosphodiesterases, 12:2233-2247, 2004. (1999). Dym et al., Molecular docking of competitive phosphodiesterase Brenner et al., “Encoded Combinatorial Chemistry.” Proc. Natl. inhibitors, Molecular Pharmacology, 61:20-25, 2002. Acad. Sci. USA, 89, 5381-5383 (1992). Haddad et al., Immunopharmacological potential of selective Bringer, A.T., “Free R value: a novel statistical quantity for assessing phosphodiesterase inhibition. I. Differential regulation of the accuracy of crystal structures.” Nature 355:472-475 (1992). lipopolysaccharide-mediated proinflammatory cytokine Buchschacher, G.L. and Panganiban, A.T., "Human (Interleukin-6 and tumor necrosis factor-O.) Biosynthesis in alveolar Immunodeficiency Virus Vectors for Inducible Expression of Foreign epithelial cells, The Journal of Pharmacology and Experimental Genes,” J. Virol. 66:2731-2739, (1992). Therapeutics, 300:559-566, 2002. Burgers, et al., “Stereochemistry of Hydrolysis of Adenosine 3',5'- Ho et al., Structure of the GAF domain, a ubiquitous signaling motif Cyclic Phosphorothioate by the Cyclic Phosphodiesterase from Beef and a new class of cyclic GMP receptor, The EMBO Journal, Heart.” J. Biol. Chem., 254:9959-9961 (1979). 19(20):5288-5299, 2000. Butcher, et al., “Adenosine 3',5'-Phosphate in Biological Materials.” Huaietal. Three-dimensional structures of PDE4D in complex with J. Biol. Chem. 237:1244-1250. roliprams and implication on inhibitor selectivity, Structure, 11:865 Capon, et al., “Designing CD4 immunoadhesins for AIDS therapy.” 873, 2003. Nature 377:525-531 (1989). Manning et al., Suppression of human inflammatory cell function by Carell et al., “New promise in combinatorial chemistry: synthesis, subtype-selective PDE4 inhibitors correlates with inhibition of characterization, and screening of Small-molecule libraries in Solu PDE4A and PDE4B, British Journal of Pharmacology, 128: 1393 tion.” Chem. Biol. 2:171-183 (1995). 1398, 1999. Chabala, J.C., “Solid-phase combinatorial chemistry and novel tag Rascon et al., Cloning and characterization of a cAMP-specific ging methods for identifying leads.” Curr Opin Biotechnol phosphodiesterase (TbPDE2B) from Trypanosoma brucei, PNAS, 6(6):633-9 (1995). 99(7):4714-4719, 2002.